FDA ad­comm votes unan­i­mous­ly in fa­vor of As­traZeneca's pre­ven­tive mAb for RSV in in­fants

The FDA’s An­timi­cro­bial Drugs Ad­vi­so­ry Com­mit­tee vot­ed 21-0 in fa­vor of the ben­e­fit-risk pro­file of As­traZeneca’s nir­se­vimab, a mon­o­clon­al an­ti­body in­tend­ed to pre­vent res­pi­ra­to­ry syn­cy­tial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.